Ocrevus Zunovo

Genentech, Inc.🇺🇸 United States

FDA Page

Effective Date: Aug 17, 2026
Approval ID: b216af61-99d0-42a3-afc2-b5bf86df1ec0
Products: 1 registered
Version: 12

Regulatory Information

Labeling Type

HUMAN PRESCRIPTION DRUG LABEL

Status

Approved

Full Title

These highlights do not include all the information needed to use OCREVUS ZUNOVO safely and effectively. See full prescribing information for OCREVUS ZUNOVO. OCREVUS ZUNOVO (ocrelizumab and hyaluronidase-ocsq) injection, for subcutaneous use Initial U.S. Approval: 2024

Quick Stats

Total Products1

Labelers2

Label Sections36

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.